Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

OTHER 94NIH 48NETWORK 6INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Clear-cell metastatic renal cell carcinoma 1Carcinoma, Renal Cell 1

Interventions

pembrolizumab 164Prednisone 129enzalutamide 125Docetaxel 122Abiraterone Acetate 94Nivolumab 92Gemcitabine 71Sunitinib 67atezolizumab 49Leuprolide 49acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 48abiraterone 48Cisplatin 48Sorafenib 39radium Ra 223 dichloride 38Ipilimumab 38darolutamide 37apalutamide 37Carboplatin 37Prednisolone 33Everolimus 33Axitinib 32avelumab 31pazopanib 30cabozantinib 30Bevacizumab 30Paclitaxel 29enfortumab vedotin 28bicalutamide 28Cyclophosphamide 26

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Specimen Handling × Genitourinary × Clear all
NCT06399419 2024-05-30

CBM588 Capsules in Combination With Nivolumab and Ipilimumab for the Treatment of Advanced Stage Kidney Cancer

Osel, Inc.

Phase 1 Recruiting
28 enrolled
Genitourinary

Clear-cell metastatic renal cell carcinoma, Carcinoma, Renal Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡